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Background  and  purpose      Early  migration  of  joint  replace-
ments is an effect of poor fixation and can predict late loosen-
ing. By reducing the bone resorption after implantation of a joint 
replacement, it should be possible to enhance the initial fixation of 
the implant. We studied the effect of once-weekly treatment with 
alendronate after knee replacement.
Patients and methods   We recruited 60 patients (60 knees) with 
gonarthrosis who were scheduled for a total knee replacement. 
They were operated on with identical implants and uncemented 
fixation. 30 patients were treated with a bisphosphonate (alendro-
nate) and 30 patients underwent placebo treatment. The treat-
ment started postoperatively and continued on a weekly basis 
for 6 months. The fixation of the implants was measured with 
repeated radiostereometry for 2 years.
Results     There  was  no  difference  in  migration  of  implants 
between the two groups.
Conclusion   With uncemented fixation of knee implants, no 
benefit of once-weekly treatment with alendronate, starting post-
operatively, could be seen during a 2-year follow-up period.  

Early migration of total joint replacements can be predictive 
of  late  loosening  (Freeman  and  Plante-Bordeneuve  1994, 
Kärrholm et al. 1994, Ryd et al. 1995, Stocks et al. 1995). 
This indicates that the risk of loosening is determined perop-
eratively (Ritter et al. 1999) or that crucial pathophysiological 
events occurring during the first postoperative months deter-
mine the risk of late loosening (Mjöberg et al. 1994, van der 
Vis et al. 1998a).
From radiostereometric (RSA) studies, it has been estab-
lished that tibial components migrate postoperatively (Ryd et 
al. 1995, Ryd 1986, Nilsson et al. 1991, Hilding et al. 1995), 
mainly  by  sinking  into  the  bone  bed.  Most  implants  have 
become settled by 6 months to 1 year, but some continue to 
migrate. A study of 143 knee implants followed longitudinally 
by RSA showed that all knees that were finally revised due 
to aseptic loosening had been migrating continuously since 
the  primary  implantation  (Ryd  et  al.  1995).  Furthermore, 
continuous migration is associated with inducible displace-
ment, i.e. immediate motion between implant and bone upon 
loading (Hilding et al. 1995). Since the tibial component of a 
knee prosthesis, or the cement surrounding it, rests directly on 
bone postoperatively, inducible displacement suggests that the 
superficial layer of the bone has been resorbed and replaced by 
soft tissue (Levitz et al. 1995).
The tibial bone bed is likely to be necrotic after surgery, 
because of trauma and damaged microcirculation. Thus, the 
remodeling that ensues has similarities with fracture repair or 
bone modeling rather than with normal remodeling. The cou-
pling between resorption and new bone formation, which is 
seen in normal remodeling, cannot be expected here. Thus, if 
the necrotic bone trabeculi are resorbed before new ones are 
produced, softening and collapse may occur. This may reduce 
the mechanical support of the prosthesis. If this scenario is 
correct, reducing resorption would be a more efficacious way 
of inhibiting or preventing loosening of implants than address-
ing the pressure in the effective joint space, i.e. the peripros-
thetic regions that are accessible to joint fluid or the wear 
particles generated in all joint replacements. Bisphosphonates 
are effective inhibitors of bone resorption (Wise et al. 2005). 
Enhancing effects of bisphosphonates on postoperative bone 
mineral density in distal femurs and proximal tibias after joint 
replacement have already been shown (Wang et al. 2006). The 
effect on fixation of implants, as measured by RSA, has been 
studied with cemented prostheses and a bisphosphonate (clo-
dronate) given daily (Hilding et al. 2000). The aims of our 
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prosthesis and to simplify the treatment by using alendronate 
administered on a weekly basis. The treatment period was 
from surgery to 6 months. The primary effect variable was 
the maximal total point motion, as measured by RSA after 2 
years.
Patients and methods
60  patients  were  recruited  for  this  study,  after  performing 
power calculations (see below). Inclusion criteria were gonar-
throsis stage 3–5 according to Ahlbäck (1968), and age 50–80 
years.  Exclusion  criteria  were  cortisone  or  bisphosphonate 
medication, rheumatoid arthritis or any other systemic illness 
affecting the skeleton, or generally poor health. Patients were 
randomly allocated to the treatment (alendronate) group or a 
placebo group. The patients were randomized after surgery by 
opening a sealed envelope, when the operative procedure had 
ascertained that the case was suitable for uncemented fixation. 
Age and sex distribution were similar in the 2 groups (Table 
1). The patients were informed before they were to be operated 
with total knee arthroplasty, and written consent was obtained. 
Merck, Sharp and Dohme provided the tablets, either alendo-
nate (70 mg) or placebo. The unit catering for clinical trials at 
the pharmacy of Lund University Hospital packed and labeled 
the tablets, and neither the patients nor the investigators were 
aware of the coding. 
2  surgeons  performed  the  operations  in  a  standardized 
manner  with  an  uncemented,  non-hydroxyapatite  coated, 
porous-coated total knee prosthesis (Duracon; Stryker Inc.). 
Tantalum markers of 0.8 mm were implanted in the proxi-
mal tibia (8–10 markers) and in the plastic insert (4 markers). 
Radiographs for RSA were taken on the fifth to seventh post-
operative day, and at 6 weeks, 3 and 6 months, and 1 and 2 
years. 2 films were taken simultaneously at a 90° angle with 
the knee inside a calibration cage, according to standard RSA. 
The digitization of the radiographs and the calculations by 
the  programs  X-ray,  Kindat,  and  winRSA  were  performed 
in Lund. The ethics committee of Lund University and the 
Swedish Medical Products Agency approved the protocol of 
the study.
On the day after the operation, the patients started the oral 
medication according to the routine for weekly osteoporosis 
treatment.
In  order  to  secure  patient  compliance  a  nurse  had  regu-
lar telephone contact with the patients, to ensure that they 
remembered to take their tablets. The tablets were given to the 
patients on 3 occasions, the first when leaving hospital after 
surgery, the second at the 6-week follow-up, and the third after 
3 months. After the treatment period, the patient compliance 
regarding the pharmacological treatment was calculated from 
the amount of tablets in the packages that were returned.
Statistics
The power analysis was mainly based on another study deal-
ing with the specific type of uncemented prosthesis to be used 
in  this  study.  Prosthetic  migration  (as  maximal  total  point 
motion, n = 14) was log-normally distributed with an SD of 
0.20. A decrease of 30% meant a difference in log value of 
0.15. This yielded a power of 83% to find a significant (p = 
0.05) decrease in migration with 2 groups of 30 patients.
Results were analyzed according to the intention-to-treat 
principle  (Hollis  and  Campbell  1999),  so  that  all  patients 
were considered to belong to the group to which they were 
originally randomized, regardless of whether they took take 
their tablets or not. Maximum total point motion (MTPM) at 
2 years served as primary effect variable, but at all time points 
the results of segment motion with 6 degrees of freedom were 
also studied. Segment motion was analyzed using Student’s t-
test. The primary effect variable was not normally distributed 
in both groups, and was tested by Mann-Whitney U-test.
Results
In the alendronate group, 24 patients (14 females) remained 
after  exclusion  due  to  the  onset  of  severe  disease  causing 
inability to fulfill treatment (2), RSA problems (3), or unwill-
ingness to complete the study (1). The numbers for the placebo 
group were 21 (14 females) after exclusion of 9 patients (onset 
of severe disease (2), RSA problems (3), lost or unwillingness 
to complete the study (4).
Patient compliance regarding the pharmacological treatment 
was 90% in both groups. 2 patients in each group took less 
than 75% of the tablets. Both groups had similar RSA findings 
and no statistically significant difference was found (Figures 
1–3). We found no significant differences regarding maximal 
total point motion (MTPM) at the 1- and 2-year follow-up 
RSA examinations (Table 2). 
Discussion
The migration found in this study, as measured by RSA, was 
of the same magnitude as in other studies of uncemented non-
hydroxyapatite  coated  knee  implants  (Nilsson  et  al.  1991, 
Hilding et al. 1995, Carlsson et al. 2005).
After surgery, the superficial layer of the bone bed is likely 
to be necrotic and avascular due to the mechanical and ther-
mal trauma of the surgery. In uncemented replacement, the 
Table 1. Demographic data
   Mean age  No. of patients
  at surgery  at surgery         at follow-up
Alendronate  68 (51–80)  30 (17 F)  24 (14 F)
Placebo  69 (54–80)  30 (18 F)  21 (14 F)Acta Orthopaedica 2009; 80 (1): 41–45  43
bone bed is usually spared from the high-pressure lavage and 
from the toxic and thermal trauma of polymethylmetacrylate 
(Mjöberg 1994). On the other hand, the mechanical loading 
of the trabeculae underlying the prosthesis will be unevenly 
possibly  disadvantageous  events  is  to  inhibit  bone  resorp-
tion with bisphosphonates (Wise et al. 2005). A study of clo-
dronate given daily for 6 months postoperatively after knee 
replacement showed less migration, using RSA, in the treated 
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Figure 1. Rotation of the tibial components in 3 
directions during the observation period.
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Figure 2. Translation of the tibial component 
in 3 directions during the observation period.
Figure  3.  The  movement  of  the  single 
marker that moves the most, maximal total 
point motion (MTPM). 
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distributed, leading to local overload, 
microfractures and increased sinking, 
compared  to  cemented  prostheses. 
Regardless of whether the prosthesis 
is cemented or not, loss of primary 
stability will lead to formation of a 
fibrous  membrane,  and  micromo-
tion will prevent osseous anchorage 
from being re-established. The mem-
brane  thus  formed  may  then  allow 
further osteolysis with time, due to 
fluid  pressure  effects  (Robertsson 
et al. 1997, Aspenberg and van der 
Vis 1998, Van der Vis et al. 1998b) 
or  possibly  effects  from  particles 
entering the membrane (Horowitz et 
al. 1991, Kadoya et al. 1997). These 
secondary  phenomena  may  lead  to 
clinical loosening.
Several authors (Levitz et al. 1995, 
Regner et al. 1999, Li and Nilsson 
2000, Abu-Rajab  et  al.  2006)  have 
described  periprosthetic  osteope-
nia after knee replacement. It could 
be argued that this bone loss should 
compromise fixation of the prosthe-
sis. However, this has not been con-
firmed in studies of revision rate or 
clinical scoring.
One way of avoiding some of these 44  Acta Orthopaedica 2009; 80 (1): 41–45
group (Hilding et al. 2000). All prostheses in that study were 
implanted with cement and the patients had to take the medi-
cation daily for 6 months. Weekly medication with alendro-
nate, as in our study, would simplify the treatment. 
In a Cochrane review it was concluded that bisphosphonate 
treatment reduced periprosthetic bone loss to a higher degree 
in cemented arthroplasties than in uncemented ones (Bhan-
dari et al. 2005). One possible explanation for this may be that 
the thermal and toxic trauma from the cement increases bone 
trauma. This might induce a more intense remodeling reaction 
than after an operation without cement. The lack of an effect 
of the bisphosphonate in our study might be explained in sev-
eral different ways. The study appears not to have been under-
powered, as the confidence interval for a difference between 
the groups was reasonably small. Experiences from a previous 
study with clodronate and cemented prostheses indicate that 
50 patients may be enough to show a decrease by 25% (p = 
0.01) (Hilding et al. 2000).
Although we tried to ensure good compliance to the treat-
ment protocol, we cannot be absolutely sure that the patients 
were  actually  treated  as  planned.  The  medication  was  not 
started until the first postoperative day, since we had to know 
if the fixation had been done without cement before including 
the patient. This is an obvious difference compared to the study 
by Hilding et al. (2000), where lower migrations of the tibial 
components in the bisphosphonate-treated group were found. 
We had hypothesized that the choice of using uncemented 
prostheses would be an even better model to test the effects 
of the bisphosphonates, because uncemented implants migrate 
more initially, and should therefore have a wider margin for 
improvement.  Our  results  do  not  support  this  theory.  One 
reason for this may be that mechanical fracture of bone tra-
beculi (rather than bone resorption) causes a large part of the 
migration of uncemented prostheses, making the advantage 
of bisphosphonates too small to be measured. There is also 
the possibility that the treatment dose was too low. We used 
the dose recommended for treatment of osteoporosis, the dose 
that has also shown effects in other pathological conditions 
such as osteonecrosis of the femoral head (Lai et al. 2005). 
In the study by Hilding et al. (2000), clodronate was used at a 
dose recommended for treating hypercalcemia and metastatic 
bone destruction. This can be regarded as a rather high dose. 
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